WO2007127204A3 - Méthodes et compositions concernant une immunostimulation - Google Patents

Méthodes et compositions concernant une immunostimulation Download PDF

Info

Publication number
WO2007127204A3
WO2007127204A3 PCT/US2007/009947 US2007009947W WO2007127204A3 WO 2007127204 A3 WO2007127204 A3 WO 2007127204A3 US 2007009947 W US2007009947 W US 2007009947W WO 2007127204 A3 WO2007127204 A3 WO 2007127204A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulation
methods
compositions relating
relating
compositions
Prior art date
Application number
PCT/US2007/009947
Other languages
English (en)
Other versions
WO2007127204A2 (fr
Inventor
Michael I Jesson
Paul A Mclean
Glenn T Miller
Barry Jones
Original Assignee
Dara Biosciences Inc
Michael I Jesson
Paul A Mclean
Glenn T Miller
Barry Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dara Biosciences Inc, Michael I Jesson, Paul A Mclean, Glenn T Miller, Barry Jones filed Critical Dara Biosciences Inc
Publication of WO2007127204A2 publication Critical patent/WO2007127204A2/fr
Publication of WO2007127204A3 publication Critical patent/WO2007127204A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes d'immunostimulation qui impliquent une inhibition de DPP8 et/ou 9.
PCT/US2007/009947 2006-04-24 2007-04-24 Méthodes et compositions concernant une immunostimulation WO2007127204A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79437106P 2006-04-24 2006-04-24
US60/794,371 2006-04-24

Publications (2)

Publication Number Publication Date
WO2007127204A2 WO2007127204A2 (fr) 2007-11-08
WO2007127204A3 true WO2007127204A3 (fr) 2008-11-20

Family

ID=38656140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009947 WO2007127204A2 (fr) 2006-04-24 2007-04-24 Méthodes et compositions concernant une immunostimulation

Country Status (1)

Country Link
WO (1) WO2007127204A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10100053A1 (de) * 2001-01-02 2002-08-22 Keyneurotek Ag I G Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen
EP2014651A1 (fr) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Composants et procédés de modulation de Rho GTPases
US20110046071A1 (en) * 2008-03-05 2011-02-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
WO2010022017A2 (fr) * 2008-08-19 2010-02-25 Hartmut Geiger Procédé et composition pour optimiser la mobilisation des cellules souches hématopoïétiques
EP2366394A1 (fr) * 2010-03-17 2011-09-21 IMTM GmbH Caractérisation et validation d'inhibiteurs et de ligands de la dipeptidyl-aminopeptidase de type IV (DP IV)
NZ739503A (en) 2015-07-16 2023-06-30 Bioxcel Therapeutics Inc A novel approach for treatment of cancer using immunomodulation
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
WO2018187698A2 (fr) * 2017-04-07 2018-10-11 Trustees Of Tufts College Polythérapies utilisant des agents anticancéreux dépendant de la caspase-1 et des antagonistes de pge2
WO2020018540A1 (fr) 2018-07-17 2020-01-23 Stc.Unm Immunogène egfrviii et ses procédés d'utilisation
WO2022187241A1 (fr) * 2021-03-01 2022-09-09 Washington University Compositions et procédés de ciblage de card8

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147130A1 (en) * 1997-05-07 2002-10-10 Huber Brigitte T. Treatment of hiv
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
WO2005106487A1 (fr) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Agents utilises dans le diagnostic et le traitement des maladies associees a la dipeptidyl-peptidase 9 (dpp9)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147130A1 (en) * 1997-05-07 2002-10-10 Huber Brigitte T. Treatment of hiv
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
WO2005106487A1 (fr) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Agents utilises dans le diagnostic et le traitement des maladies associees a la dipeptidyl-peptidase 9 (dpp9)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIAANG W.-T. ET AL.: "Novel Isoindoline Compounds for Potent and Selective Inhibition of Prolyl Dipeptidase DPP8", BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 687 - 691, XP004739680 *
LANKAS ET AL.: "Dipeptidyl Peptidase IV Inhibition for the treatment of Type 2 Diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9", DIABETES, vol. 54, 2005, pages 2988 - 2994, XP055028657, DOI: doi:10.2337/diabetes.54.10.2988 *
LU I.-L. ET AL.: "Acid Analogues as Potent Dipeptidyl Peptidase IV and 8 inhibitors", BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 3271 - 3275, XP004947953 *
SEDO ET AL.: "Quaternary Benzo[c]phenanthridine Alkaloids as Inhibitors of Dipeptidyl Peptidase IV-Like Activity Bearing Enzymes in Human Blood Plasma and Glioma Cell Lines", PHYSIOL. RES., vol. 52, 2003, pages 367 - 372 *

Also Published As

Publication number Publication date
WO2007127204A2 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007127204A3 (fr) Méthodes et compositions concernant une immunostimulation
WO2008067219A3 (fr) Modulateurs quinazolinones de tgr5
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
WO2007054623A3 (fr) Inhibiteurs de signalisation du herisson des mammiferes
HK1200698A1 (en) Compositions comprising kakadu plum extract or acai berry extract
WO2007079215A3 (fr) Procedes et compositions destines a eliminer l'arsenic et les metaux lourds de l'eau
WO2008002674A3 (fr) Compositions bicycliques et procédés de modulation d'une cascade de kinases
WO2007127834A3 (fr) Compositions et leurs méthodes d'élaboration
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
IL191997A0 (en) Inhibitors of iap
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2007095116A3 (fr) Compositions de verre pour verres de protection et procedes de fabrication et d'utilisation de ces compositions
EP1868633A4 (fr) Compositions et procedes permettant d'inhiber les proteines dishevelled
EP2041064A4 (fr) Alkyl lactyl lactates et leurs procédés de préparation
WO2007139871A3 (fr) Méthodes et matières pour l'élaboration de simvastatine et de ses composés
IL195761A0 (en) Compositions and methods relating to novel compounds and targets thereof
WO2009009041A3 (fr) Compositions et procédés permettant de moduler une cascade de kinases
IL196465A0 (en) Compositions and methods for the treatment of mucositis
EP1996682A4 (fr) Procédé permettant d'améliorer des propriétés inhibitrices de la corrosion de compositions lubrifiantes
WO2008070616A3 (fr) Procédés et compositions liés au hif-1a
EP1979395A4 (fr) Procede pour la production de phosphonates/copolycarbonates sequences et de leurs compositions
WO2007081751A9 (fr) Compositions et procedes destines au traitement du cancer
WO2007140205A3 (fr) Procédés de traitement de fibrose
HK1162483A1 (zh) 抑制激酶通路的組合物和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07776113

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07776113

Country of ref document: EP

Kind code of ref document: A2